MannKind | MNKD - Interest Expense On Debt


MannKind reported $14.82M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Adma Biologics USD 2.1M 474K Mar/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Insmed USD 18.84M 1.24M Jun/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.89M 1.55M Mar/2026
MannKind USD 14.82M 2.38M Jun/2026
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 667M 4M Jun/2026
Sanofi EUR 287M 109M Jun/2026
Xencor USD 7.35M 2.65M Jun/2026